<SEC-DOCUMENT>0001193125-14-188748.txt : 20140508
<SEC-HEADER>0001193125-14-188748.hdr.sgml : 20140508
<ACCEPTANCE-DATETIME>20140508074433
ACCESSION NUMBER:		0001193125-14-188748
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140508
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140508
DATE AS OF CHANGE:		20140508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		14822983

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 240
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d722491d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;8, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-31791</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3562325</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678)&nbsp;620-3186 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7 &#150; REGULATION FD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;8, 2014, Galectin Therapeutics&nbsp;Inc. (the &#147;Company&#148;) issued the attached press release, which is being furnished and
not filed, and is attached hereto as Exhibit 99.1. Among other things, the press release provides the website and phone number for accessing the audio portion of a corporate update that will follow the Company&#146;s 2014 Annual Meeting of
Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this report is being furnished pursuant to this Item&nbsp;7.01 and shall not be deemed &#147;filed&#148;
for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities
Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND EXHIBITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Financial Statements of Businesses Acquired. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Pro Forma
Financial Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Shell Company Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated May 8, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;8, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jack W. Callicutt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Jack W. Callicutt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d722491dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g722491img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company&#146;s Annual
Meeting of Shareholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Atlanta, GA., May&nbsp;8, 2014</B> &#150; Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:45 A.M.
Eastern Time on Wednesday, May&nbsp;14, 2014, to provide a corporate update following the Company&#146;s Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment
community on the Company&#146;s pipeline of galectin inhibitor compounds and progress in development of treatments for liver fibrosis and cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following his presentation, Dr.&nbsp;Traber will answer questions from shareholders present at the meeting. Shareholders not attending the meeting may submit
questions in advance for Dr.&nbsp;Traber&#146;s consideration; questions should be submitted via email to IR@galectintherapeutics.com no later than May&nbsp;13, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conference call and presentation will be webcast live over the internet and can be accessed by logging on to the Galectin Therapeutics website at
www.galectintherapeutics.com. The call can also be accessed by dialing (888)&nbsp;897-5640 (within the United&nbsp;States) or (719)&nbsp;457-6284 (outside the United States). The passcode for participants is 341247. Please log in approximately
10&nbsp;minutes before the event to ensure a timely connection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The webcast will also be archived on the Company&#146;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics
(NASDAQ: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive
scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our
lead compounds in liver fibrosis and cancer. Additional information is available at http://www.galectintherapeutics.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Harold&nbsp;H. Shlevin
(678)-615-3213 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Operating Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shlevin@galectintherapeutics.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g722491img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g722491img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+@"_`P$1``(1`0,1`?_$`,@```$$`@,!````````
M``````D`!P@*!08!`PL$`0$``00#`0$`````````````!`$"`P4&!P@)"A``
M``8"`0,"!`,$!`45`````0(#!`4&!P@1`!()(1,Q%!4*018746$B&'$EMWBA
M0B-V.9&QT3(S0U.3)$0U5;75)I8W1[@9.A$``0($!`,%`P4+#`,``````0`"
M$1(#!"$Q$P5!%`9182(R%7$S!X&1P2,(\*&Q\4)2<[,T=#71X6)R@E.#)%1E
MM18F=CC_V@`,`P$``A$#$0`_`#Q^:+R_W+2^V82TFTXJT!E/R([;2\56\55^
M:*#^LXGB+3.$K43D"Z1:(F-(N)&3%8(QBJ)43D9N'3GN00!%8B<;$GA`Q+=Z
MI%V;R:9,R5Y'MA)9LWDKE.YEO=M8X5K4ZY3(N^A,182JLI7J-5:M%NCG3:J+
M,UWJA`Y,9,O:BF1.9D#Q\WS5BJN<D>+B\V7$UMHS4\W_`"C7J[6O(&JF>(R+
MX<R&/7%:N,C89G#-JL3!N+>*L57=LBL'IDQ=-'3<5"]$6-\&>VF8MV]/LA;"
M9P2G8>X6C;K9R.94.P.R/GF)ZM`WX\=7L4)."LV!CMJ&T3%D`G2*85"'$0#D
M``B,KT1+HB%MY?\`%-PNNBFQ%^QYL!GG7J]X,PME[+50L&"\@.*,,S.5.DR5
MA;15X;H,G1K'7UCP_9[('043%8YR*%-P($43_MD[O<\C^'S7R[9"MECO-QL-
MNS6^G+5;9N2L5AF'A\KVHIG,E,2[EW(/%^"@'<HH;@```].`Z(C\]$2Z(ET1
M+HBX,;M#G@1]0#@/4?4>/\'1%IU%R!3,G52)O./K'%6^GSZ;I6%L<(Y(\BI-
M-B_=1;M1HY)_"J1"09+(F$/\=,P=7!L1'@L+ZLKI(8PBHR6#>C7JK;A4W2"9
MGYM#/E[J#BY0$2G69!6OGC$F<I))MG-C(`M6\BZCX1TJF02BGVI"!CE,)2CJ
M:6^6E7<?2&APN"TN[H-_&N64>CM_=TK4ZS<ZGZ'3KMHD1\<[R0(#LB#'%3([
M@,0!*/(?M_`?AZA^T.ML,UQ6MDNWJU9$NB(87EWR_G7"6F\K;];IZ9@,OR&3
ML5T^JKU^(C)V8D%[;:FT,>%CXN6CY)DY<RWS`(D[DOX3&`>0`!'K0]1W%S;;
M>'6CY*SJC6@^V*[_`/LV].=&=3?$9UIU]3H5>F:&W7%>H*SI6#3D@XF(Q`<8
M8P6DZ?XCW0Q]0FN8/(#NI874@G'MIV4QI%L\<4V@4-H)2KE9W.ZH5EG*3LLF
M4P%=$;KM&A#\IE]WX]6[-M^]4FZ^[70>TX@?RQ3XO=??"G<MXN-@^$_3=C;;
M70<6B[>:CG/A@"T30`XB,8YX#.2#/R-Z.6&<_*$=LUCU.8=.#1R*II"0CF!W
M1P]LI&UB>L&\&!S'.`$/\P)1-\.>N3:%3L70"AOOG6]X\.4*?SWK7MI/3>.(
M"/&>L=&MT7CQ[(Q<$J*1C3%1MQJXBE8&;<BH*?*N>Y<Z7^Y**#_".2FUGE<!
M,JH$0>5+?X?4-AI80'U`?RK1/A_Y5ZRZ=/L")W,*>2[>2TV^>CI[/4L_9LL/
MYZLS9N:L4I(I)JI86OEFKKWO0KJ1A-&3L0W<%*/)#F3X.!BB)1&FR&0S'X40
MH](\@+[E?>!9`R+>EEY9''&7MEXZF,9$YW*,-'X&QQ;<94UFT25$2()198SY
ME("@`%<B*@`!A$>H"HO2&*7M``Y$WP]3<<CP`!SZ``>O'/\`3T1(P<AQZ_$!
MY`.1`0$!`>/W"'1%'[776G&VK\#D>M8O1EFD+DW-N4L]SC&4>).TF-UR]8#6
M>W-X8$FS8&4$:8444;H#WF2]PP"<W1$./)/DKS!D;R&W+QI:1XLHT]E#"V-H
M_*.Q>=L]K7./P[B^,GD()S6JC`5^EM4K'?[E-MK*S4+P_C&*0&4+[JAD%0*1
M-)F[RD;0>/G:C5?">_\`C?!%FPCN5=/TLQ9L5K2\OL*[HV3EWT/'1\'D[%F1
MG<\Z/#O7E@:<2$;*G*F@<ZADA%(Z8D1'_);_`*.S>S^Z%L7_`&26SHB%S]J_
M_H5-8_\`./-7]K-LZ(I!TWR/9CW5V$SOA'QR5+$$_CG5NR!C_..UN='MN?XU
M<99,+@'.+<.T3'R["P9!D:ZFV,>4EW$G&QC<1*5(%P43,8BP.+O*7DW&/D$K
M_C.\@&/,9XYS1EVF%R!K#FK#$Y8WN&<ZPX+2[9S67%?NR8VS'U_:.*^^3*T7
M=OVSI5#L35**J/N$3^[Y>32E:>7?"6NE&HDEL'N=M!,_0,`ZZ5R:85M63(10
M49"^9'MS]-\VH&,Z^"2ZSM^=LY<*)M5@004%-0Q2*,>X&Z7E$T#U\F-N<T84
MU)SSBRA2-<6RSB/75WG&)RQ5*I8)AG#.Y^K6^YDF*S<BU1P_3,]]Z(BDU$0,
ML4R1"B'1%@O+?O)MW2O%#9-T=)8#']0JEFUZA\FVBT9M-:X#+^-:UDM&L,X4
ME*QTTA'40ZR`T;6P>XTJ_;MV#A(#@FX$"AT1:MX.KGO0OXZ=!&P8<UW?8.<8
M2K#@][<YVO@9:DH)S]7=C+.*0IB`U>)9G\@<!50-.&0Y4,85AXXZ#`Q08&89
MIH)#RL;"0?FNU8T+SAX\<%X=O&8*S/OF>>OU4:9DOQ<5GJE_FFI:598:BTX8
M4'L[2%FKQBY.L5,IC^@]Y3#A-M0-P+J1O,!I$T,8',*6R_O:=F[;FUJG(.>'
MFG,9"X1@9<L(F"E[YJO)+MUXQ\`R6Q6&-6<49MQ'74ZY'W2]77,LK5Y6G6.U
MSQ*]#)%Q=%U!1Y:8`SQRV!1TA/-%2J+=HH@4IE`SQ4,@.S6;PSO'O?O/@#%6
M9](\!8.IM:N.,ZA9I;*NW,YDNNU"TWJ1@&+JW5O$6-*%%KWV9I-?L:KA@C9Y
M9['M'IT#&:H.D2^^:BJL!XQ_*]DW:W9':?0S;3"56P/N?J,HUD[I'8XM+RX8
MGOM,>N8MFWM-,DIE-"<8%!2;8K"W<"N8[5\D<#E.51,A$:B?K,!9B1)9^+92
MA8*;8V.(!\D18L=.Q@+!'2K8J@"0KUB+@QDCB`B0P]P<"`"&.I2I5@&U6AS0
M8X]HR*DVUY=V8J<I4?3-6DZF\M,"6.A,T]Q@(JISYI-F;A?-A)'7B,E9!CC3
M$K*!3?P397VF=FO,S')S3R4F$1[2O"0\>]1;-$Q$Q2#[B@%`_`ALK>G2=3#7
M-$O8HH#FR!CG-:S@#`._K=OWL25'+4'QI9<W1QW/Y$Q_><>UB'@;8YI[EA;D
MYX))=XTCXV54<MS146Z3*U.G($((&,!AX'\.>LG-4>Q51#K!XCM_[1BRI83G
M]IL>R6*Z.N[<5RE.)"[_`$AH9VK[H)NB$A"JR35B;D&:3@RB;,#&]D""//4:
MI7B\NI@0]B)HA\"NS(?^[^%1_<!;ES_AA0Z4[CQC4$6<8*UY<UA+1%_#YQ]$
M4X^*_"3L11+),S4EE7#[Q"1QGEZDH)LOS;[J;_(>+KA1XQXI[L,0ORC*2L*2
MB_KW>R0W:`FX`;J=6,^J#"(EAV1XJ]PEJ81+#5`RR9`Q^7)5[C4-_P"*C[M>
MJV?)#<*OAW9C-=OLE(N$B91I!2E2VL@[!7TG1)!0I&O_`(;RS/&CGPB/"1T!
M,?@HE'J(J+TA4?@;]HFY/P(B'N<`4_`B80``X^`<<=$5>?[@'5>H&T3W$W+I
MF2\_XFV&Q7BF,ME8N>,M@\O4F#]RGR<.R;0KS'\/<&M#6:RT4X5;.#IQR+E1
M14BHJ&4*`B1#B^U3U^=;-ZI.MW-C<Y;,YCRW6-E;76<?MKEL7F-Y2:Q&4.LT
MYRU%>CIW%&NV4\@_LSDRY)5%X@<H$+[8=H")$:;8+R6UF!W*5T%TEQ)6]B]]
MK!7&EDRJX?23:FXBU]HL:V:J-K;L5D>*8/;(_&-8S#4[.NQJ+J2<"^02*9L*
MQ!$BKT_<5XDSY2LG^'RW["[(2.<+I:]YJZS-5*[1Z_C+"F/TVMDQD[.TQ]4F
M@35P<.7!W7LKR4W.2+MPBBGP5'U(!%;.\E9N[QW[V$`![OY0=C1X]/4"XDMO
M/P$>/0/QX^/1$$W[?:2LL-]N57Y6EBN%RC,;;?R-3^5`1=_F5C8,CNH/Y0"<
MJF<A(II=G;Z]W'1$/#[374G679W0/,UJRQ`VZR9)B=I[=&V-W$YBS'1%!:N:
M-1)2)4D8N@7ZK1SITNH\<F%RN@=R<>2F.)2E`"*S<Q\0WCMC,MX\SD.NR$YF
M'%,K%SF.,A6[)N9+Q9:;)0K\\I%JPKZX9"G!;(-)$YERH>J(J&,82#R/1%7%
M96"1E/O0'K/)IA*A`ZW.X3$#:2`?829GUY2EV(P8+"5(%';J1FENXG/+A17_
M`!@'@BNP"@1=`R3@B:R2Q!(JBJFF=,Z:G(G343,"J9RG*(`8!Y`?7]O1$&3[
MAP2CX6M_R$+V`3$$,`%$O8``7)-'X`H>GH`%]./PXZ(M\\$("'AY\>(#\?Y:
MZ7_KOAZ(@K;[?_K-\3W]W6T?]@;&]$4[ONI/]"AL[_G-@[^V*F]$1+O%KR7Q
ML:%E,`@/\I.``X_9QC2M\!_J=$5=W03U^[)\KY?Q-KU!``_@']6:\_'\>B*V
M[>\DT;&R544O5DC:RC=[M7\<U=:44]E"8NUK.Y2K=<05,'M%D)MRU,BV*<2@
MHN)2`/<8H"15=_-'J=<Z?FQ]L_7H9[+8SR0SA6]QF&*#E=*E7*'9(P1PG/;[
MP9Q5C:-6XMW!@(0'('3[N1+S+HUF,$'1S1#XU\WTV8U:I\K2<,76#K58EIYQ
M9Y!I(U6NS0FE7#-DP<.0D)1$RJ2)T&*8]AC`!./B/671H'M168O&!E#<S-U&
MM69]I;&U"@S;=BWQ7#FIT)4W<BR;^Z\E[VHLT0;.QA'!!*W:BIP14"'5+_#V
MB,2LUC7P9DB?+R69RR#K]HWF_-^')N.B;U3J]!2U6FW4>SG6")I&R0<>=R#)
MR"K-X16/D#]G/)1Y`0_;UI]YO*^W[77O+>!JL9''VA=N_`;H_8^OOBYLG2?4
M=)U;:+RY<U[6O-,P%*HZ(<`2(0X9JJI@3S2>0^]72QPECRY6G3*-PEL9<FY$
M<;U)L<MCQ_@?(=VJS@RB+(@J),[)!-5CD'DJI2"0P"4P\]76?76^5B[6%.`M
M:M00`S93+AP[0OI7U3]D#X$;+MU*ZL[&]GK[SM]#&Y>84J^X6]O6'M-.HX`\
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M,T^@L`[.8>W";V5*_4G,6497$MNHA;7-05@5CTYA*K6PRK:KSD$F9DLS0=`O
M%&^7.W34*0X$6Q>7#Q,^2??NGZY9T9YEPU.[(:SYTKV5J-K)!IOZ3KK#0#5[
M&/I2,C,E6**?WVWY%5D8)BHYF)0L;&N&B:J36/:&$ICD4X,X4'R\YQU`V$QU
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MVQFQFOGD=TAR#3\3[_:O.61:_P#J`W??I;G"F1IY!=&A9`>0R"\O$&%I)OF)
M'J:2Z1V+Y5!4@=J:R9(%2AK.P_E2O=:"IN_'MCC!F3'C,(V0RM=]K*'?\)5J
M4,@4CBUQ=6H,,[RE<XY`0.LVBE&T6JL<"(K.T2B=4"#');?L;H*XSYXS\LZ"
M3.8;+8;%DS#<M2I#-=W,M,SDMD>2D?S;^>)YI[QU4HQU>DRJF8-S"1E'<-T/
MX4B=$XPXJ`WBYQIYA-:-<,!Z.91P-K=CRHZYK-:LYV?;YF)D4F1\15V9=RC&
MO5'#\1%1\O#W>RLE210RLJ^09Q[8PNQ:+."@W%W\$44]BO'GY?\`.'EJUI\H
M$9C;2.LIZQ5$E%KV&7NPN2I)>VP+I&],IUW+7)'!S=.-E7[:_.1:^TQ42;&;
MI=X*]QQZK`H<,3DIF>9_4WR+^1W2XNH6(\=ZQ4AME2+QS8\OW.]9MN2RM-MU
M3M+:T/:91HR)Q,H2SQ"CN*:%),NE&2AB'4+\D`]I@HBEUX]J/O7KUI74<#9Y
MQ?KVOD[7S$%-QKB1WCC,=KE:GEE6F5D86/<W![.8QB)#&YG!H]HFL*"$R7E1
M10H<%`@E6!0?-;?';Y=,)^7?8;R?3..]*9N-V;KY*);\1QFP&24'-,J9"T-H
MRDX.U.,*]DW.1C.CH**IK,D$7:BYRE%$.TX,D@1FI#?=:6BQTGQ#72Y5*9DJ
MW;*IL!KE8ZW885XJPEH&>ALB,Y"*EHQ^@9-=J]8/FY%$E""!BG*`AT5$(3QL
M_=U8+NF,(?!?E4I,G%V=O%MZW(YWJ53)><?9$8E32:%?9-Q\S(M,P,TL`=SI
M9@U?LW!^5?:;B(]$1/3^2W[8&K".3V>5=9W4JW'ZHE&,,<Y-F),SI(IA(5K1
MUZDLP1=`(?PE%J4H#_3U9JN'!WS(@/>8G[KJ/SSC2R:I>-FOVW'6/K@P-5+U
ML19V!*E;W]0=(C'OZSB>ILUE'5.CY=D<6ZTF\,F_!L8R2+9`QO<ZN!+A$HK9
MWDN(4GAER(4@=I2X#PX`!R(\`5W0RAZF$3#P4`#D1YZTG4O\`NOT7TA>A_LH
M?_0G3,/]:_\`4552GU5_]3;K_=MV_P#_`(NY9ZZ(L`<?W"O^I<OLU\0`?1++
M_P!@VK_EK->GCUZ37YWDNB)=$2Z(ET1+HBX'CCU^'50A`=@4W=^QO7,C#6F]
MG!^O'5NPM[0E&M)%U'M921:,9&/9(3)6BB2DA&MS21E@;F."9ETTS&`P%XZJ
M''+@I-"^KV9)H1#R,QF/8ASZ3XZ@[XAL-*3ZU@4E,<[]YQ"ER2%CFDG4/$4V
MPQI8:K('4DUDU*HB@J=`\:H`M3I&'_)@(]:#96-KMJU!^3<GY@1@N>=8;AZ=
MZ718*1;6VF+A*/,\U)G&#8S=\<%V8TS+9<09%V.*YK"UDQW8=_X'%/U1U<WY
MYFM/LGT7$<?'KU^"D&T@W5KT9:Y<#NF_S;,"_,J';IF`HE-CH[A4HW=P!`AU
MX&=\33IY+-NW3]GN>V[52MW27C=A=7(:(,(IU[DF:$/$X-/`Y"*D92=G)W(^
M1YRN4G$=FGJ'6LP7'"5AR&W=-D4X.PT6+64G+,^8O$TT1J:-G3^D`"2RC\5C
M%7!N*')@V%.]?7KU;9P@VGQ^[\:XU>;%;[;M=M7KUR+NYH"LU@RE+G-[8Q\)
MAP.2UJA;59&N%#NV27F&JY6JO5+#>J260E\NQ#1!6V4#*#K'4R>0<2-<CD(^
MI+M6:LF@\[U72A$3-P:BLHB![:=?4MGW.0:#Q'`J1>=,V-G?T["A<.=6J4FU
M(!KHP<V8`9Q.7<(XK"*[FS"U#=6N%Q8VEY:-VIKVK<Q%KVM[7V1I*QR];BXV
M\Q#F8JR4FXB02M;1<[5PT:N1*53L[^"]\9VZ-8QSP?=U`S,PB[Z%)=T32J7+
M6:[AS.SNNV&&(8S5BQQ!A&+'98'!=LSNT2IR5SQ_:,<.4\OU;..+<'M:Y7)5
M:;K5AE<RUH;E2+,PGSQ3"20ABUUN[4>MU&0.T5VADTR'!5,XY:]_4HL+6C%M
M27MQ(!'\_%8[?HQE_2H7M.X#=JJV52O,<'-%$P>PB(Q!(@<H'N*<!GL5;V<W
M@ZLW7#<K2IG-&1,CXZ(UE+$P%:&=4FL62U1-I;MV[9TK)UFXQ-9.JAWG:OF@
M+D!5#T,`3!N#W5J0(A,#@<,>'#(K6W&Q652QNG6=TZI3I4&.CB3XR6D&)P<T
M@1S$".]-O%[>7>Z(ZLOJACVO,$\YYCRUC&UQ\_:G*AZ\3%##(?SCF%D(ZOK)
MR'U9[1E%4S*I(&*0Q"&(`B8Q8PO!4IVQC@ZM#YLUL*O3EE:W-_3N*]0FUI4W
MB`SCW$YB([.)7P5[8BO8\=Y88,*!)L;K:MWOT!AXI]?I6R1%NR+:ZC6+&WMI
MI.5:B-(JJ%5,9RO&,VQR-U&IR($,=8#=64J[?&T"#M<#MB>WV=RK>].W%9]G
M5JURVW]'UR`($,:78"!Q.&!,(QQR6_Y1VCL>%V^,FV2\=1=7>Y`M4_5BS3ZX
M*GQT@]93D5$U:/&^M:\XBX"8R#%2"CV)1FRQB)U&QF1E_FCIE/*NKQM.II\2
M_C]WX5#V[:[?<ZE06-1SZ3:8=EC'&,1F0(8P[4'?[MP0_P#I@RKQR(#FC`G'
M`"/'%Y0'D>/@'IU.=F%QAHA$=Z\G83`!C<^G(\\?'X@'[.0ZHJKCN+\?Q_H'
M_8Z(NYL8OS+?U_YPC^`_@J7]W1%[*?DR$`\-&10X$1#`V'2B4`'D#`[H9NWM
M]!Y$!]`ZT'5'\`NOT?TA>BOLF@N^T-TR`9?\X_'_``*JI3ZK<ER9<B]HB<^M
MNX'\("`F`0U>RS_`/P_B_=UTE;9M_<:_ZER^SWQ"IN&QV1U`?_(-IX_[M9KT
M\>O1B_.NET1+HB71$NB)=$2Z(OA?`W%HZ!8SDB8MU@.9G\T+HI124`QFGR93
M.?F@#GV_:`5>_CM#NXZKBKVS\/H4/M1&^K:+?,8ZSOK4[:FS!<0RZ$\3+94B
M9I!^7\_&<?J:S:\VD[X2?4_DN0Y`GN<!V]:W:18BG4],B:>H9HS>;CY_Q=BY
M-U.[?B;/_L`MP>6^HEY>.CC_`'1.&?FQ6C3+;247%X^KO[,"X[9T$]T#LS9R
M7:;V:U^04E/EV0A\T*`Q'R_L<PW:#;O'_:]1H;1K/@?K>:\7G]](V'=Y98?D
M_+%;B;K3EZ`:VCI^CU=.'+3<C-5U3@9XS:N?UOYHR3IU)OKB.4[^XHCZP!9_
MU)41R(QJQ<C_`*??K$-=:&>.I<T<R-C_`//I8+Y8'@%7]WW?:^8)\SV=3:7)
MZ]?2]]`:F<,OFC#LQ6INCU%Z;:"]%/D^5.@7Z,^AJ/C")U)9Y\Q&$8>%-,]0
MT6_EENB4D]?CK\?-+H+*X?$R[]12S>.7F0+FC"KM`O8V0,S`D)?DDS)?4A-V
M_P`/?U'I#;>1?(3R>,T9_EA''YE-KNZM_P"Q434;1];Y82!O+2Z,IA&4Z4)8
M^8QA#N4?L[M]>CT"62PL[F"ICO%KVYS:XDG6:FBY<FL;U3E9-A%_4:Y,R2E^
MFB$9I.?IJ14R.SD,\61,`B&DW1NVFWJ"U<`[FZ>K&?S80&1Q/=AVKE&R5.HF
M[@#O+&N'H=R+<,Y>&B6U)7>%[6R!\^9FAD"(*1B[;20E/O[::D#JKCGNF$O4
MA/%R-^L(;$G)"?ILKV/8]')?YV28BP^@`S0]OY$"_*@+?OYWCO3I:D_EUO%Y
MO/`??AV8??7$Z)ZNUZ!H@3<@_3]SI<MXM3CIPSFF\481QE6]WYIK<:*Q8VN<
MG>B3)<J2?Z82"1,NCE)3)Q*W/&G_`)`D5''NH*+5`)`KWW4"L08"?N[2]H]9
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M_0&Z>4).WC!-X.R#.+V<F6/EGT`6RU?\RER&5S&@V(R/80C/^E"H^@A['"7?
MU6N-NUSJDZW&$W;QAAG#-1+!W4?,#D&T-;3;++R\(2NEDQA/":,OCSFQ3;>4
M]+QY+:>V(GDX<PK74H;?0QGEIPN1C1Q;8$RF-'`0Q8@YM_>:5X`OMD%'_A>"
M];5<2=&8S>:./M573Z=]DGP']>XN_'_>=Y>?B/Q_J;GX_#]W142^G_9)_P#7
MN+O^)WF_[FZ(N0COLE.0XG<6\\AQRCO)QSR''/=#=O'/QY]/V]$5N;8\FI!]
M/;`GL,M&):E#0Z@$ZL]"W#&!1P5@_P`IF.%<24MOLF.#+M]L@K\"'N!QW=:_
M=>1.WU?4\+&7Q^;+^SXOF78'PL=URWK_`&QWPU:7=<"N>4'U.-21\?V@BCY)
MO>$#Y8(,V+VOVY!;!+?IK)48\Z.-<NA*`BGLB`ACHV,K6&5SC]48%;>R3&PR
M@J=G_*?;`?EP%;L#KA%%O0$1I.QT*D/?^[D,^8_-C_2[,5[&ZAK_`&ZC8T/7
=*+A9>H6FGCL_[3S='EAX*A,#<Z0,?J_SR&17_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
